NCT03485547 2026-02-02
Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Dana-Farber Cancer Institute
Phase 1 Completed
Dana-Farber Cancer Institute
City of Hope Medical Center
Fred Hutchinson Cancer Center